AboutContact usRSS
dotsbydots
SEARCHCONTACT US

Buzz

Most popular

Daily
Weekly
1
Nvidia on verge of completing $700 million acquisition of Run:ai
2
Nvidia announces $700 million acquisition of Run:ai
3
Israeli Billionaire Hires Black Cube to Spy on Former Partner Company Vale
4
Nagomi Security raises $23 million Series A for proactive defense platform
5
Bill Ackman: "Israel needs support more than ever and I can help"
More news

CAR-T

7 stories about CAR-T
פרופסור זליג אשחר

Scientist Quarrel Over Kite Pharma Sale Royalties to be Settled Out of Court

28.05.18|Zohar Shahar Levy
Israeli immunologist Zelig Eshhar, who holds the patent for Kite Pharma’s anti-cancer technology, has been sued by a former student for infringement of patent rights
פרופסור זליג אשחר

Scientist’s Ex-Wife Joins Legal Melee Over Kite Pharma Windfall

16.01.18|Zohar Shahar Levy
Zelig Eshhar, the patent holder for Kite Pharma’s anti-cancer technology, is currently being sued by a former student for infringement of patent rights
מייסד קייט פארמה אריה בלדגרין

Gilead Builds on Kite Pharma Acquisition, Buys Second CAR-T Therapy Company

10.12.17|Lilach Baumer
California-based Cell Design Labs will be acquired in a deal valued at up to $567 million
default image

Kite Pharma’s Cancer Drug Gets Regulatory Nod

19.10.17|Lilach Baumer
The cancer-treatment company, bought by Gilead Science in August for $11.9 billion, will sell one treatment course of the drug for $373,000
מוסף שבועי 14.9.17 פרופ' גידי גרוס

Kite Pharma Sale Triggers Scientist Quarrel

02.10.17|Zohar Shahar Levy
Zelig Eshhar who patented the company’s core technology is now being sued by his former PhD student and current pharma entrepreneur
default image

Meet Kite Pharma's CEO, the Man Bringing Hope to Hodgkin's Lymphoma Patients

30.08.17|Dror Reich
With two exits worth hundreds of millions of dollars to his name even before selling Kite Pharma for $12 billion dollars, just where will Arie Belldegrun aim next?
default image

Gilead To Buy Kite Pharma for $11.9 Billion

29.08.17|Dror Reich
The drug company is looking to diversify into cell therapy following declining hepatitis c drug sales